carl zeiss meditec ag - CZMWY

CZMWY

Close Chg Chg %
48.13 -0.29 -0.59%

Closed Market

47.85

-0.29 (0.59%)

Volume: 936.00

Last Updated:

Jan 13, 2026, 3:50 PM EDT

Company Overview: carl zeiss meditec ag - CZMWY

CZMWY Key Data

Open

$48.48

Day Range

47.80 - 48.59

52 Week Range

44.74 - 76.28

Market Cap

$4.21B

Shares Outstanding

87.54M

Public Float

N/A

Beta

1.52

Rev. Per Employee

N/A

P/E Ratio

26.97

EPS

$1.34

Yield

84.53%

Dividend

$0.41

EX-DIVIDEND DATE

Mar 28, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

2.59K

 

CZMWY Performance

1 Week
 
-0.14%
 
1 Month
 
0.73%
 
3 Months
 
-10.75%
 
1 Year
 
-3.69%
 
5 Years
 
-65.57%
 

CZMWY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About carl zeiss meditec ag - CZMWY

Carl Zeiss Meditec AG engages in the development, manufacture, and marketing of medical devices. It operates through the Ophthalmic Strategic Business Unit (SBU) and Microsurgery business SBU segments. The Ophthalmic SBU segment includes intraocular lenses, surgical visualization solutions, and medical laser and diagnostic systems. The Microsurgery SBU segment offers surgical microscopes and visualization solutions for neuro, ear, nose, and throat surgery, as well as the activities in the field of intraoperative radiotherapy. The company was founded in 2002 and is headquartered in Jena, Germany.

CZMWY At a Glance

Carl Zeiss Meditec AG
Göschwitzer Strasse 51-52
Jena, Thueringen 07745
Phone 49-3641-220331 Revenue 2.46B
Industry Medical Specialties Net Income 155.89M
Sector Health Technology 2025 Sales Growth 9.81%
Fiscal Year-end 09 / 2026 Employees 5,784
View SEC Filings

CZMWY Valuation

P/E Current 26.97
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 27.816
Price to Sales Ratio 1.763
Price to Book Ratio 1.744
Price to Cash Flow Ratio 18.72
Enterprise Value to EBITDA 11.893
Enterprise Value to Sales 2.046
Total Debt to Enterprise Value 0.142

CZMWY Efficiency

Revenue/Employee 425,190.972
Income Per Employee 26,952.776
Receivables Turnover 3.026
Total Asset Turnover 0.623

CZMWY Liquidity

Current Ratio 2.354
Quick Ratio 1.44
Cash Ratio 0.05

CZMWY Profitability

Gross Margin 52.755
Operating Margin 11.528
Pretax Margin 8.703
Net Margin 6.339
Return on Assets 3.948
Return on Equity 6.543
Return on Total Capital 4.871
Return on Invested Capital 5.127

CZMWY Capital Structure

Total Debt to Total Equity 28.697
Total Debt to Total Capital 22.298
Total Debt to Total Assets 17.557
Long-Term Debt to Equity 26.632
Long-Term Debt to Total Capital 20.694
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Carl Zeiss Meditec Ag - CZMWY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.06B 2.23B 2.24B 2.46B
Sales Growth
+4.54% +8.32% +0.50% +9.81%
Cost of Goods Sold (COGS) incl D&A
838.14M 942.40M 1.06B 1.16B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
75.43M 79.00M 143.92M 139.52M
Depreciation
42.66M 46.82M 56.27M 57.89M
Amortization of Intangibles
32.77M 32.18M 87.65M 81.63M
COGS Growth
+3.21% +12.44% +12.43% +9.66%
Gross Income
1.22B 1.29B 1.18B 1.30B
Gross Income Growth
+5.48% +5.50% -8.25% +9.95%
Gross Profit Margin
+59.26% +57.71% +52.69% +52.76%
2022 2023 2024 2025 5-year trend
SG&A Expense
779.31M 898.99M 929.93M 1.01B
Research & Development
315.01M 372.55M 371.90M 360.21M
Other SG&A
464.31M 526.44M 558.03M 653.70M
SGA Growth
+10.81% +15.36% +3.44% +9.03%
Other Operating Expense
- - - -
-
Unusual Expense
9.30M 11.20M 20.80M 21.30M
EBIT after Unusual Expense
430.48M 375.91M 229.30M 262.20M
Non Operating Income/Expense
15.58M 81.36M 66.96M (18.82M)
Non-Operating Interest Income
14.33M 29.98M 24.28M 7.25M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.84M 16.27M 31.89M 29.37M
Interest Expense Growth
-4.03% +65.35% +96.08% -7.93%
Gross Interest Expense
9.84M 16.27M 31.89M 29.37M
Interest Capitalized
- - - -
-
Pretax Income
436.23M 441.00M 264.37M 214.02M
Pretax Income Growth
+7.67% +1.09% -40.05% -19.04%
Pretax Margin
+21.20% +19.79% +11.80% +8.70%
Income Tax
116.31M 128.59M 65.81M 56.91M
Income Tax - Current - Domestic
115.98M 115.36M 88.46M 71.09M
Income Tax - Current - Foreign
- - - 8.25M
-
Income Tax - Deferred - Domestic
855.18K 13.23M (22.65M) (14.19M)
Income Tax - Deferred - Foreign
- - - (8.78M)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
319.92M 311.46M 195.28M 157.15M
Minority Interest Expense
2.16M 1.72M 1.55M 1.25M
Net Income
317.76M 309.74M 193.73M 155.89M
Net Income Growth
+12.54% -2.52% -37.45% -19.53%
Net Margin Growth
+15.45% +13.90% +8.65% +6.34%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
317.76M 309.74M 193.73M 155.89M
Preferred Dividends
- - - -
-
Net Income Available to Common
317.76M 309.74M 193.73M 155.89M
EPS (Basic)
3.5527 3.4631 2.1804 1.7809
EPS (Basic) Growth
+12.54% -2.52% -37.04% -18.32%
Basic Shares Outstanding
89.44M 89.44M 88.85M 87.54M
EPS (Diluted)
3.5527 3.4631 2.1804 1.7809
EPS (Diluted) Growth
+12.54% -2.52% -37.04% -18.32%
Diluted Shares Outstanding
89.44M 89.44M 88.85M 87.54M
EBITDA
515.21M 466.11M 394.02M 423.03M
EBITDA Growth
-2.07% -9.53% -15.46% +7.36%
EBITDA Margin
+25.04% +20.92% +17.59% +17.20%

Snapshot

Average Recommendation HOLD Average Target Price 55.169
Number of Ratings 16 Current Quarters Estimate 0.666
FY Report Date 03 / 2026 Current Year's Estimate 2.372
Last Quarter’s Earnings 0.423 Median PE on CY Estimate N/A
Year Ago Earnings 1.893 Next Fiscal Year Estimate 2.843
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 15 14
Mean Estimate 0.67 0.70 2.37 2.84
High Estimates 0.72 0.72 2.78 3.55
Low Estimate 0.63 0.68 2.09 2.51
Coefficient of Variance 6.71 2.60 8.85 9.89

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 5
OVERWEIGHT 3 3 2
HOLD 9 7 8
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Hold Hold Overweight

Carl Zeiss Meditec Ag in the News